<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="343360">
  <stage>Registered</stage>
  <submitdate>17/08/2011</submitdate>
  <approvaldate>8/09/2011</approvaldate>
  <actrnumber>ACTRN12611000962932</actrnumber>
  <trial_identification>
    <studytitle>A prospective randomized controlled trial to compare 
Pringle maneuver and selective hepatic vascular occlusion 
in Liver resection involving the hepatocaval junction</studytitle>
    <scientifictitle>compare the effect of selective hepatic vascular occlusion and Pringle maneuver in Liver resection</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>controlling intraoperative bleeding in Liver resection</healthcondition>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Surgical techniques</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>selective hepatic vascular occlusion is a method of inflow and outflow hepatic vascular occlusion in liver resection .It occurs once or twice for less than 1 hours which was decsided by the time of liver resection  .</interventions>
    <comparator>Pringle maneuver which is only inflow occlusion occurs once or twice  for less than 1 hours which was decsided by the time of   liver resection .</comparator>
    <control>Active</control>
    <interventioncode>Treatment: surgery</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Blood loss(ml) ,Blood transfusion (units)</outcome>
      <timepoint>Intraoperation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1.Complications including postoperative hemmorrhage ,bile leak ,wound infection ,etc.
2.liver, renal function
Theywill be assessed including full blood count and ultrasonic,etc.</outcome>
      <timepoint>after  surgery in one  month</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Corresponding to diagnostic standards of HCC; 2. Patients of liver tumors underwent resection with occlusion of more than one main hepatic veins; 3. liver function in  the Child-Pugh classification A or B; 4. Age 
between 18~65years 5. Haven't taken any current treatment. 6. Understanding and being willing to sign the informed consent form</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.cannot be follow-up 2.severe liver, renal, or brain dysfunction; 3.with tumor thrombi in the main trunk of portal vein4. with tumor thrombi in the hepatic vein 5.with extrahepatic metastasis</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>who had indications for partial hepatectomy at the Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital were considered included in the study</concealment>
    <sequence>create the random order for the allocation of subjects into different groups. Simple randomisation by using a randomisation table created by computerised sequence.  If stratified allocation was employed in the study, the in hospital time used for the stratification.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/06/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>160</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>China</country>
      <state>shanghai</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Eastern Hepatobiliary Surgery Hospital</primarysponsorname>
    <primarysponsoraddress>Second Military Medical University,changhai street Shanghai, China,200438</primarysponsoraddress>
    <primarysponsorcountry>China</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Eastern Hepatobiliary Surgery Hospital</fundingname>
      <fundingaddress>Second Military Medical University,changhai street Shanghai, China,200438</fundingaddress>
      <fundingcountry>China</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>Second Military Medical University</sponsorname>
      <sponsoraddress>chanhhai street ,Shanghai, China,200438</sponsoraddress>
      <sponsorcountry>China</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To  compare the effect of selective hepatic vascular exclusion (SHVE) and Pringle maneuver in Liver resection
To study the safety and efficacy of hepatic resection under selective hepatic vascular exclusion .</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethic Committee of Shanghai Eastern Hepatobiliary Surgery Hospita</ethicname>
      <ethicaddress>225 Changhai road, 200438, Shanghai,  China</ethicaddress>
      <ethicapprovaldate>10/05/2008</ethicapprovaldate>
      <hrec>ehbhky-2008013</hrec>
      <ethicsubmitdate>20/03/2008</ethicsubmitdate>
      <ethiccountry>China</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>zhouweiping</name>
      <address>225 Changhai Road, 200438, Shanghai,China</address>
      <phone>+86 021 81875524</phone>
      <fax />
      <email>ehphwp@126.com</email>
      <country>China</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>fusiyuan</name>
      <address>225 Changhai Road, 200438, Shanghai,China</address>
      <phone>+86 021 81875524</phone>
      <fax />
      <email>fusiyuan1993@yahoo.com.cn</email>
      <country>China</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>fusiyuan</name>
      <address>225 Changhai Road, 200438, Shanghai,China</address>
      <phone>+86 021 81875524</phone>
      <fax />
      <email>fusiyuan1993@yahoo.com.cn</email>
      <country>China</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>